Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colon cancer cells in the phase\u00e2 $ 3 LIGHTHOUSE CRC trial

.Competing rate of interests.S.K.: Sell and also Various Other Possession Interests: Iylon, Lutris, MolecularMatch, Navire. Consulting or even Advisory Role: AbbVie, Amal Therapies, AstraZeneca/MedImmune, Bayer Health And Wellness, Bicara Therapeutics, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Endeavor BioMedicines, Fire Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Medical Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Drugs, Lilly, Lutris, Merck, Mirati Rehabs, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Therapeutics, Servier, Xilis. Research Study Backing: Amgen (Inst), Collection BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: Formerly Pfizer. Sell as well as Other Ownership Rate Of Interests: Pfizer. J.P.: Job: Formerly Pfizer. Inventory and Other Ownership Claims: Pfizer. F.C.: Consulting or even Advisory Job: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Research Funding: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Part: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Analysis Financing: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Duty: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Drug, Terumo. H.S.W.: Consulting or even Advisory Task: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Rehabs, Erytech Pharma, Incyte, Merck KGaA, Oaktree Lifestyle Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Research Study Financing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Investigation Funding: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Drug (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Drug (Inst). H.S.: Work: Pfizer. Inventory and Other Ownership Interests: Pfizer. X.Z.: Work: Pfizer. Stock and Other Possession Claims: Pfizer. Patents, Royalties, Various Other Patent: Johns Hopkins University. P.H.: Job: Pfizer. Supply and Various Other Ownership Claims: Pfizer. T.X.: Job: Pfizer. Inventory and also Various Other Possession Stakes: Pfizer. R.Y.: Consulting or even Advisory Job: Range BioPharma/Pfizer, Mirati Rehabs, Zai Laboratory, Amgen. Research Study Backing: Selection BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapeutics (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or Advisory Task: Array BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapeutics, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapeutics, Seagen Inc., Servier, Taiho Drug, Tessa Therapy, TheraMyc. Other Relationship: Amgen, Variety Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Cells Investigation UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Converse el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Wellness KGaA, MJH Lifestyle Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapeutics, PeerView Principle for Medical Education, Pfizer, PharmaMar, Physicansu00e2 $ Learning Resource, Sanofi-Aventis, Servier, Taiho Pharmaceutical.

Articles You Can Be Interested In